hapabapa/iStock Editorial via Getty Images
Intro & Thesis
I wrote my first bullish article on Novo Nordisk A/S (NVO) back on December 20, 2024. I argued that NVO was punished just for the short term, and I saw it
Novo Nordisk: The Market Is Giving Us A Free Lunch
Summary
- Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity.
- While Q2 guidance was lowered, the underlying business remains strong with 18% year-over-year sales growth, proving that NVO's core momentum is still intact.
- Strategic catalysts like the exclusive CVS formulary win and the NovoCare direct-to-patient channel are actively working to secure future revenue and protect market share.
- Explosive international growth and a powerful R&D pipeline, featuring the promising drug amycretin, provide massive, underappreciated long-term value for the company's future.
- NVO stock currently trades at a deep, irrational discount to its peers and historical norms, offering what could be a compelling 24% upside potential.
Recommended For You
About NVO Stock
| Symbol | Last Price | % Chg |
|---|---|---|
| 61.85 | 6.27% | |
| Post | 61.98 | 0.21% |
Chart
Combination chart with 2 data series.
The chart has 1 X axis displaying Time. Data ranges from 2025-09-15 09:30:00 to 2025-09-18 16:00:00.
The chart has 1 Y axis displaying values. Data ranges from 55.55 to 62.17.
End of interactive chart.
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| 61.85 | 6.27% | |
| Post: | 61.98 | 0.21% |
| 61.83 | 7.29% | |
| 6.40 | 5.61% | |
Chart
Line chart with 3 lines.
The chart has 1 X axis displaying Time. Data ranges from 2025-09-15 09:30:00 to 2025-09-18 16:00:00.
The chart has 1 Y axis displaying values. Data ranges from -4.4 to 10.45.
End of interactive chart.
Trending Analysis
Trending News
- 1
- 2
- 3
- 4
- 5